ABSTRACT
Porokeratosis is a clonal keratinization disorder characterized by solitary, linearly arranged, or generally distributed multiple skin lesions. Previous studies showed that genetic alterations in MVK, PMVK, MVD, or FDPS-genes in the mevalonate pathway-cause hereditary porokeratosis, with skin lesions harboring germline and lesion-specific somatic variants on opposite alleles. Here, we identified non-hereditary porokeratosis associated with epigenetic silencing of FDFT1, another gene in the mevalonate pathway. Skin lesions of the generalized form had germline and lesion-specific somatic variants on opposite alleles in FDFT1, representing FDFT1-associated hereditary porokeratosis identified in this study. Conversely, lesions of the solitary or linearly arranged localized form had somatic bi-allelic promoter hypermethylation or mono-allelic promoter hypermethylation with somatic genetic alterations on opposite alleles in FDFT1, indicating non-hereditary porokeratosis. FDFT1 localization was uniformly diminished within the lesions, and lesion-derived keratinocytes showed cholesterol dependence for cell growth and altered expression of genes related to cell-cycle and epidermal development, confirming that lesions form by clonal expansion of FDFT1-deficient keratinocytes. In some individuals with the localized form, gene-specific promoter hypermethylation of FDFT1 was detected in morphologically normal epidermis adjacent to methylation-related lesions but not distal to these lesions, suggesting that asymptomatic somatic epigenetic mosaicism of FDFT1 predisposes certain skin areas to the disease. Finally, consistent with its genetic etiology, topical statin treatment ameliorated lesions in FDFT1-deficient porokeratosis. In conclusion, we identified bi-allelic genetic and/or epigenetic alterations of FDFT1 as a cause of porokeratosis and shed light on the pathogenesis of skin mosaicism involving clonal expansion of epigenetically altered cells.
Subject(s)
DNA Methylation , Epigenesis, Genetic , Keratinocytes , Mosaicism , Porokeratosis , Promoter Regions, Genetic , Porokeratosis/genetics , Porokeratosis/pathology , Humans , Keratinocytes/metabolism , Keratinocytes/pathology , Promoter Regions, Genetic/genetics , Male , Alleles , FemaleABSTRACT
Porokeratotic adnexal ostial nevus (PAON) is a rare adnexal hamartoma characterized by keratotic papules following Blaschko's lines, typically located on the unilateral distal extremities. Cutaneous somatic GJB2 mutations have been linked to the pathogenesis of PAON. However, the genetic mechanism underlying bilateral or extended forms, which are less documented, remains unknown. In this study, we presented two cases of PAON with widespread cutaneous lesions and scalp involvement, and demonstrated the presence of GJB2 mosaic mutations in both patients. We further investigated the mosaic frequency in different tissues to gain insights into the mutation events contributing to the phenotype of widespread PAON. Our findings suggest that early postzygotic mutation causing mosaic GJB2 mutations may contribute to the widespread phenotype of PAON, thereby enriching the disease spectrum and mutation profile of PAON.
Subject(s)
Connexin 26 , Mosaicism , Mutation , Porokeratosis , Skin Neoplasms , Humans , Connexin 26/genetics , Female , Porokeratosis/genetics , Porokeratosis/pathology , Porokeratosis/diagnosis , Male , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Connexins/genetics , Scalp/pathology , Nevus/genetics , Nevus/pathology , Nevus/diagnosis , Skin/pathology , Phenotype , AdultSubject(s)
Porokeratosis , Humans , Follow-Up Studies , Mutation/genetics , Porokeratosis/diagnosis , Porokeratosis/genetics , SkinABSTRACT
BACKGROUND: Porokeratosis is a rare chronic progressive hypokeratotic skin disease, possibly related to the mevalonate pathway. Variations in four enzymes, including phosphomevalonate kinase (PMVK) may alter this pathway, ultimately leading to porokeratosis. OBJECTIVES: The aim of the study was to identify the causative gene variant of porokeratosis in a Chinese family and investigate its population frequency and pathogenicity. METHOD: In this study, Sanger sequencing was used to identify the gene variant causative of porokeratosis; its population frequency was investigated by polymerase chain reaction-restriction fragment length polymorphism in 4 patients and three normal individuals as well as in 100 normal unrelated controls; finally, the pathogenicity of the mutation and the associated structural changes were predicted. RESULTS: We identified a novel heterozygous missense variant, c.207G>T (p. Lys69Asn) in the PMVK gene. This variant was found in all patients but not in the normal individuals in this family or in the 100 controls. In silico analysis indicated that the variant was pathogenic; p.Lys69Asn changed the length of the α-helix and the hydrogen bond pattern compared with the wild-type protein. CONCLUSIONS: The novel variant c.207G>T (p. Lys69Asn) in the PMVK gene was the causative variant in this porokeratosis family. This finding provides further evidence for the genetic basis of this disease.
Subject(s)
Porokeratosis , Humans , Porokeratosis/genetics , Mutation , Phosphotransferases (Phosphate Group Acceptor)/genetics , Mutation, Missense , PedigreeSubject(s)
Hamartoma , Keratosis , Porokeratosis , Humans , Infant, Newborn , Connexins/genetics , Hamartoma/genetics , Mutation , Porokeratosis/geneticsSubject(s)
Hidradenitis Suppurativa , Porokeratosis , Humans , Hidradenitis Suppurativa/complications , Hidradenitis Suppurativa/drug therapy , Porokeratosis/drug therapy , Porokeratosis/genetics , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Interleukin 1 Receptor Antagonist Protein/genetics , Skin , Mutation , Pyrin/geneticsABSTRACT
Porokeratotic eccrine ostial and dermal duct nevus (PEODDN) is a rare type of epidermal nevus involving the eccrine acrosyringia. It typically presents as asymptomatic linear keratotic papules and plaques along the lines of Blaschko and predominantly affects the extremities. This disease has recently been linked to somatic mutations within the GJB2 locus. Only four GJB2 mutations have been previously documented for PEODDN, and the underlying genetic basis remains inconclusive. Herein, we report an 18-year-old female with a hyperkeratotic plaque on the dorsa of the proximal interphalangeal joint of her right ring finger, as well as multiple small hyperkeratotic papules linearly distributed on the lateral sides of her fingers occurring since birth. Histopathological results revealed prominent parakeratotic cornoid lamella-like tiers at the opening of the eccrine secretory ducts. Whole-exome sequencing of the affected skin tissue revealed a heterozygous germline mutation and a postzygotic somatic mutation in GJB2. In summary, this study presents a case of PEODDN with compound heterozygous mutations in GJB2, which broadens the genetic spectrum of this disease entity and implies a possible role for second-hit mutations in the pathogenesis of PEODDN.
Subject(s)
Hamartoma , Keratosis , Nevus , Parakeratosis , Porokeratosis , Skin Neoplasms , Sweat Gland Diseases , Adolescent , Female , Humans , Eccrine Glands/pathology , Hamartoma/pathology , Keratosis/pathology , Mutation , Nevus/genetics , Nevus/pathology , Parakeratosis/pathology , Porokeratosis/genetics , Porokeratosis/pathology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Sweat Gland Diseases/pathologyABSTRACT
BACKGROUND: Porokeratosis is a clinically heterogeneous group of keratinization disorders with a genetic background mainly affecting the mevalonate pathway, which is involved in the synthesis of cholesterol, an essential component for the formation of the extracellular lipid lamellae in the stratum corneum. Porokeratosis is reportedly associated with an increased risk of keratinocyte cancer, but to date, no large epidemiological studies have been conducted to further address this association. OBJECTIVES: The first objective was to characterize a cohort of patients diagnosed with porokeratosis at the Department of Dermatology and Venereology, Sahlgrenska University Hospital (SU), Gothenburg, Sweden. The second objective was to conduct a nationwide registry-based cohort study to investigate the association, if any, between porokeratosis and the cutaneous malignancies squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and melanoma. METHODS: For the SU cohort, the hospital registry was searched for patients with a diagnosis of porokeratosis recorded between 2016 and 2020. Clinical data were extracted from the records of the identified patients. For the nationwide cohort, national registries were searched to identify patients with a diagnosis of porokeratosis between 2001 and 2020. A tenfold control cohort was formed by Statistics Sweden. The data was cross-referenced with the Swedish Cancer Register to study the associations between porokeratosis and SCC, BCC and melanoma. RESULTS: Disseminated superficial actinic porokeratosis was the most common clinical type among the 108 patients in the SU cohort. In the nationwide search, 2277 patients with porokeratosis were identified (prevalence 1/4132). Porokeratosis was associated with an increased risk for SCC, BCC and melanoma with hazard ratios (95% CI) of 4.3 (3.4-5.4), 2.42 (1.97-2.98) and 1.83 (1.18-2.82), respectively, in the patient cohort, compared to the matched control group. CONCLUSION: Porokeratosis is a common genodermatosis, and it is associated with an enhanced risk of skin cancer.
Subject(s)
Carcinoma, Basal Cell , Carcinoma, Squamous Cell , Melanoma , Porokeratosis , Skin Neoplasms , Humans , Porokeratosis/complications , Porokeratosis/genetics , Porokeratosis/diagnosis , Cohort Studies , Melanoma/epidemiology , Melanoma/genetics , Skin Neoplasms/epidemiology , Skin Neoplasms/genetics , Skin Neoplasms/complications , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/etiology , Keratinocytes/pathologySubject(s)
Porokeratosis , Humans , Mutation , Mutation, Missense , Pedigree , Porokeratosis/genetics , ChinaABSTRACT
Porokeratotic eccrine ostial and dermal duct nevus (PEODDN) is a rare eccrine hamartoma; the etiology is incompletely understood. A patient presented with congenital, widespread PEODDN. Clinical assessment, histopathologic, cytogenetic, and molecular genetic investigations on affected cells were pursued. Histopathology confirmed PEODDN, and chromosomal microarray on affected tissues identified a mosaic 3p26.3p25.3 deletion in affected tissues. This 11Mb deletion encompasses 47 OMIM genes. We propose that this and other chromosomal deletions may be implicated in some cases of PEODDN, suggesting locus heterogeneity and underscoring the importance of incorporating cytogenetic and molecular investigations into the multidisciplinary care of individuals with suspected mosaic genetic skin disorders.
Subject(s)
Hamartoma , Nevus , Porokeratosis , Skin Neoplasms , Sweat Gland Diseases , Eccrine Glands , Humans , Porokeratosis/geneticsABSTRACT
BACKGROUND AND AIMS: Porokeratosis (PK) is a heterogeneous group of cutaneous keratinization disorders and has five clinical subtypes. DSAP is the most common clinical subtype and is characterized by multiple small, annular, anhidrotic, keratotic lesions predominantly on sun-exposed areas of the skin. It is an autosomal dominantly inherited epidermal keratinization disorder. However, studies on its molecular basis is limited. MATERIALS AND METHODS: We performed mutation analysis of genes in four pedigrees and three sporadic cases of DSAP in the Chinese population. Genomic DNA was extracted from blood samples obtained from patients, unaffected family members, and 100 unrelated individuals. All exons and flanking intron sequences of the mevalonate kinase (MVK) and farnesyl diphosphate synthase (FDPS) genes were amplified. RESULTS: One missense mutation in exon 7 (C.G677A) of the MVK gene was identified in pedigree 3, and one missense mutation in exon 5 (C.C535T) of the FDPS gene was identified in sporadic case 3. No mutation was detected in the MVK and FDPS genes in the remaining three pedigrees and two sporadic cases with DSAP. CONCLUSION: Our results may be useful for genetic counseling and prenatal diagnosis of affected families and for expanding the repertoire of MVK and FDPS mutations underlying DSAP.
Subject(s)
Geranyltranstransferase/genetics , Phosphotransferases (Alcohol Group Acceptor) , Porokeratosis , China , Humans , Mutation, Missense , Pedigree , Phosphotransferases (Alcohol Group Acceptor)/genetics , Porokeratosis/geneticsABSTRACT
Porokeratoses are a heterogeneous group of keratinization disorders. For linear porokeratosis and disseminated superficial actinic porokeratosis, a heterozygous pathogenic germline variant in a mevalonate pathway gene and a postzygotic second hit mutation present in affected skin have been shown to be the patho-genetic mechanism for the development of the lesions. However, the molecular mechanism leading to development of porokeratosis plantaris, palmaris et disseminata is not known. This study analysed a cohort of 4 patients with linear porokeratosis and 3 patients with porokeratosis plantaris, palmaris et disseminata, and performed mutation analyses of DNA extracted from blood samples and skin biopsies. All of the study patients carried the heterozygous germline variant c.70+5G>A in the MVD gene. Loss of heterozygosity due to a second hit mutation was found in affected skin of 3 patients with linear porokeratosis and 2 patients with porokeratosis plantaris, palmaris et disseminata. These results suggest that porokeratosis plantaris, palmaris et disseminata shares the same pathogenetic mechanism as other porokeratosis subtypes and belongs to the phenotypic spectrum of MVD-associated porokeratosis.
Subject(s)
Porokeratosis , DNA Mutational Analysis , Genitalia , Humans , Mutation , Porokeratosis/diagnosis , Porokeratosis/genetics , SkinSubject(s)
Porokeratosis/genetics , Adolescent , Adult , Age of Onset , Aged , Asian People/genetics , Child , Child, Preschool , Cohort Studies , DNA Mutational Analysis/instrumentation , DNA Mutational Analysis/statistics & numerical data , Female , High-Throughput Nucleotide Sequencing , Humans , Infant , Infant, Newborn , Lab-On-A-Chip Devices , Male , Middle Aged , Mutation Rate , Pedigree , Polymorphism, Single Nucleotide , Porokeratosis/blood , Porokeratosis/diagnosis , Porokeratosis/pathology , Skin/pathology , Young AdultSubject(s)
Porokeratosis/genetics , Skin Neoplasms/genetics , Adolescent , Adult , Child , Connexin 26 , Female , Humans , Male , Mevalonic Acid , Middle Aged , Porokeratosis/diagnosis , Skin , Skin Neoplasms/diagnosis , Exome SequencingABSTRACT
Vesicular nucleotide transporter (VNUT) is the last identified member of the SLC17 organic anion transporter family, which plays a central role in vesicular storage in ATP-secreting cells. The discovery of VNUT demonstrated that, despite having been neglected for a long time, vesicular ATP release represents a major pathway for purinergic chemical transmission, which had been mainly attributed to ATP permeation channels. This article summarizes recent advances in our understanding of the mechanism of VNUT and its physiopathological roles as well as the development of inhibitors. Regulating the activity and/or the expression of VNUT represents a new and promising therapeutic strategy for the treatment of multiple diseases.
Subject(s)
Adenosine Triphosphate/metabolism , Nucleotide Transport Proteins/metabolism , Animals , Circadian Rhythm , Clodronic Acid/metabolism , Humans , Inflammation/metabolism , Inflammation/pathology , Neurons/metabolism , Nucleotide Transport Proteins/antagonists & inhibitors , Nucleotide Transport Proteins/genetics , Pain Perception/physiology , Porokeratosis/genetics , Porokeratosis/pathologyABSTRACT
BACKGROUND: Porokeratosis is associated with mevalonate pathway gene mutations. Therapeutic options are few and often limited in efficacy. We hypothesized that topical therapy that aims to replenish cholesterol, an essential mevalonate pathway end-product, and block the accumulation of mevalonate pathway toxic metabolites could alleviate porokeratosis. OBJECTIVE: To study the efficacy of topical cholesterol/lovastatin in different variants of porokeratosis. METHODS: We enrolled a series of 5 porokeratosis patients,1 with disseminated superficial actinic porokeratosis, 2 with porokeratosis palmaris et plantaris disseminata, and 2 with linear porokeratosis. Patients were genotyped before initiation of therapy. Patients then applied topical cholesterol/lovastatin twice daily to a unilaterally defined treatment area for up to 3 months. The response was evaluated and patients photographed at every visit. RESULTS: Three patients had MVD mutations, and 2 patients had PMVK mutations. Treatment with topical cholesterol/lovastatin (but not cholesterol alone) resulted in near complete clearance of disseminated superficial actinic porokeratosis lesions after 4 weeks of therapy and moderate improvement of porokeratosis palmaris et plantaris disseminata lesions and linear porokeratosis lesions. There were no adverse events. LIMITATIONS: Case series design with a small number of patients. CONCLUSION: Topical cholesterol/lovastatin is an effective and well-tolerated therapy for porokeratosis that underscores the utility of a pathogenesis-based therapy that replaces deficient end products and prevents accumulation of potentially toxic precursors.
Subject(s)
Anticholesteremic Agents/administration & dosage , Carboxy-Lyases/genetics , Cholesterol/administration & dosage , Lovastatin/administration & dosage , Porokeratosis/drug therapy , Porokeratosis/genetics , Administration, Cutaneous , Adult , Child, Preschool , Drug Combinations , Genotype , Humans , Middle Aged , Mutation , Ointments , Phosphotransferases (Phosphate Group Acceptor)/genetics , Young AdultABSTRACT
Introducción: La Poroqueratosis de Mibelli es una entidad rara en nuestro país, incluida en el grupo de las genodermatosis, por ser un trastorno hereditario de la queratinización. Es de gran interés para varias ramas de la medicina: genética, dermatología, medicina interna entre otras. Caso clínico: Se presenta un caso en una familia portadora de esta enfermedad genética con carácter autosómico dominante, se identificaron 7 miembros afectados en 3 generaciones, sin complicaciones. El propósito fue confirmado a través del estudio histopatológico. Conclusiones: Aunque no es un problema relevante en el municipio y no tiene complicaciones que comprometan la vida de los pacientes, sí pueden verse afectados según la localización de las lesiones, por lo que es de gran importancia el asesoramiento genético a los miembros de la familia para evaluar el riesgo genético, para poder realizar la profilaxis y control de los miembros afectados y su descendencia(AU)
Introduction: Porokeratosis of Mibelli is a rare condition in our country. It is included in the group of genodermatoses, being as it is an inherited keratinization disorder. This skin condition if of great interest to several medical specialties, such as genetics, dermatology, internal medicine, and others. Clinical case: A case is presented of a family carrying this genetic disease of an autosomal dominant nature. Seven affected members were identified in three generations without any complications. The purpose was confirmed via histopathological examination. Conclusions: Although the study condition is not a relevant problem in the municipality and does not have complications threatening the lives of patients, these may be affected depending on the location of the lesions. Therefore, genetic counseling is of great importance, so that family members may evaluate the genetic risk, perform the corresponding prophylactic actions, and control affected members and their offspring(AU)